Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

Ex Input:
"In his address to a joint session of Congress, President Barack Obama brought up the most explosive charge to emerge in the health care debate: the specter of ""death panels."" ""Some of people’s concerns (about the health care legislation) have grown out of bogus claims spread by those whose only agenda is to kill reform at any cost,"" Obama told lawmakers and a national television audience on Sept. 9, 2009. ""The best example is the claim, made not just by radio and cable talk show hosts, but by prominent politicians, that we plan to set up panels of bureaucrats with the power to kill off senior citizens. Now, such a charge would be laughable if it weren’t so cynical and irresponsible. It is a lie, plain and simple."" The president was referring to a notion most prominently raised by former Alaska Republican Gov. Sarah Palin in a note posted on her Facebook page on Aug. 7, 2009. ""And who will suffer the most when they ration care?"" Palin wrote. ""The sick, the elderly, and the disabled, of course. The America I know and love is not one in which my parents or my baby with Down Syndrome will have to stand in front of Obama's 'death panel' so his bureaucrats can decide, based on a subjective judgment of their 'level of productivity in society,' whether they are worthy of health care. Such a system is downright evil."" We have read all 1,000-plus pages of the Democratic bill and examined versions in various committees. There is no panel in any version of the health care bills in Congress that judges a person's ""level of productivity in society"" to determine whether someone is ""worthy"" of health care. When we first  assessed  Palin's claim on Aug. 7, 2009, we gave it our lowest rating — . Palin may have jumped to a conclusion about the Obama administration's efforts to promote comparative effectiveness research. Such research has nothing to do with evaluating patients for ""worthiness."" Rather, comparative effectiveness research finds out which treatments work better than others. The health reform bill being considered in the House of Representatives says that a Comparative Effectiveness Research Center shall ""conduct, support, and synthesize research"" that looks at ""outcomes, effectiveness, and appropriateness of health care services and procedures in order to identify the manner in which diseases, disorders, and other health conditions can most effectively and appropriately be prevented, diagnosed, treated, and managed clinically."" The idea here, which Obama and his budget director Peter Orszag have discussed many times, is to make it easier for doctors, health care workers, insurance companies and patients to find out which treatments are the most effective, as determined by clinical studies and other research. The House bill states in the section creating the Comparative Effectiveness Research Center and an oversight commission that ""nothing in this section shall be consd to permit the Commission or the Center to mandate coverage, reimbursement, or other policies for any public or private payer."" In other words, comparative effectiveness research will tell you whether treatment A is better than treatment B. But the bill as written won't mandate which treatment doctors and patients have to select. Nothing has emerged to suggest to us that the death panels claim is any more  today than it was when Palin first floated it. We still rate it as  today. In our book, that counts as a ""lie, plain and simple."" So we find Obama's claim ."

Ex Output:
The claim ... that we plan to set up panels of bureaucrats with the power to  kill off senior citizens ... is a lie, plain and simple.


Ex Input:
The study to be published on Wednesday in the Journal of Neuroscience differs from many other pot-related research projects that are focused on chronic, heavy users of cannabis. The collaborative effort between Northwestern University’s medical school, Massachusetts General Hospital and Harvard Medical School showed a direct correlation between the number of times users smoked and abnormalities in the brain. “What we’re seeing is changes in people who are 18 to 25 in core brain regions that you never, ever want to fool around with,” said co-senior study author Dr. Hans Beiter, professor of psychiatry and behavioral sciences at Northwestern University. In particular, the study identified changes to the nucleus accumbens and the nucleus amygdala, regions of the brain that are key to regulating emotion and motivation, in marijuana users who smoke between one and seven joints a week. The researchers found changes to the volume, shape and density of those brain regions. But more studies are needed to determine how those changes may have long-term consequences and whether they can be fixed with abstinence, Beiter said. “Our hypothesis from this early work is that these changes may be an early sign of what later becomes amotivation, where people aren’t focused on their goals,” he said. The study, which was funded in part by the National Institute on Drug Abuse and the White House Office of National Drug Control Policy, comes as access to pot is expanding following 2012 votes in Washington state and Colorado to legalize its recreational use. The drug remains illegal under federal law. Medical pot is allowed in 20 U.S. states. Pot legalization advocates make the argument that marijuana is safer than alcohol a central part of their campaigns. Other research has found drinking alcohol alters the brain, Beiter said. But while researchers do not know exactly how the mental rewiring seen in pot users affects their lives, the study shows it physically changes the brain in ways that differ from drinking, he said. This latest study fits with other research showing marijuana use has significant effects on young people because their brains are still developing, and Beiter said he has become convinced that marijuana should only be used by people under 30 if they need it to manage pain from a terminal illness.

Ex Output:
Casual pot use causes brain abnormalities in the young: study.


Ex Input:
The vaccine uses an inactivated whole H5N1 virus from Vietnam, said an official for Sinovac Biotech, which jointly developed the vaccine with China’s Centers for Disease Control. “We finished our second trial in November. We checked our 402 participants for antibodies and they met international standards used in the United States and the European Union both for safety and immune response,” Sinovac’s publicity supervisor Liu Peicheng told Reuters by telephone. China’s State Food and Drug Administration said on Wednesday it had authorized production of the vaccine. The vaccine was used in amounts of 5, 10 and 15 micrograms but the 10 microgram dose was found to be ideal. “The 10 and 15 microgram doses met standards but we decided on 10 as it’s good enough. It would use less antigen,” said Liu. Antigens are substances like toxins, viruses and bacteria that stimulate the production of antibodies when introduced into the body. But they can be difficult to culture and scientists have been trying to fix that by using boosters, or adjuvants. Participants in the Chinese trial were between the ages of 18 and 60. Liu said only some minor side effects were recorded, in line with those sometimes seen with seasonal flu vaccines. He did not elaborate. For years now, experts have warned of a flu pandemic and many have held up the H5N1 virus as a prime candidate because people have no immunity against this bird virus, and because of the high mortality rate associated with it so far. The virus has infected 376 people in 14 countries since late 2003 and killed 238 of them, or 63 percent. An eventual vaccine to protect people against a flu pandemic can only be made 4-6 months after the start of such a disaster, when the culprit virus strain has been identified. But human populations still need some form of protection in those initial months of a pandemic, and drug companies are in a race to design what are known as “prepandemic” vaccines, which is what Sinovac is producing now. The company is conducting tests to see if the vaccine may offer cross protection against other strains of the virus found in Indonesia, Turkey and Anhui province in China, Liu said. “This vaccine is reserved for emergencies in the country and we have to get instructions on how much to produce,” he added. On March 2, GlaxoSmithKline company said a vaccine it designed to protect people against H5N1 may be effective in warding off a few different sub-types of the virus.

Ex Output:

China approves bird flu vaccine for humans.